Bictegravir 30 mg / emtricitabine 120 mg / tenofovir alafenamide 15 mg [Biktarvy]
RxNorm 2584355

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2584355 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: bictegravir 30 mg / emtricitabine 120 mg / tenofovir alafenamide 15 mg [Biktarvy].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Bictegravir 30 mg / emtricitabine 120 mg / tenofovir alafenamide 15 mg [Biktarvy]
AUI:12710269
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Bictegravir 30 mg / emtricitabine 120 mg / tenofovir alafenamide 15 mg [Biktarvy]
(Atom ID: 12710269)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
bictegravir 30 MG / emtricitabine 120 MG / tenofovir alafenamide 15 MG [Biktarvy]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2584355
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12710269
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2584355
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Bictegravir, Emtricitabine, and Tenofovir


The combination of bictegravir, emtricitabine, and tenofovir is used to treat human immunodeficiency virus (HIV) infection in certain adults and children weighing at least 55 pounds (25 kg) who have not received antiretroviral treatment in the past or who have been stable on other antiretroviral treatment(s). Bictegravir is in a class of medications called integrase strand transfer inhibitors (INSTIs). Emtricitabine and tenofovir are in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). The combination of bictegravir, emtricitabine, and tenofovir works by decreasing the amount of HIV in the body. Although bictegravir, emtricitabine, and tenofovir will not cure HIV, these medications may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of getting or transmitting the HIV virus to other people.
[Learn More]


* Please review the disclaimer below.